trending Market Intelligence /marketintelligence/en/news-insights/trending/3_c6iJa2-R3BFSxkHhNb3w2 content esgSubNav
In This List

Alexion Pharmaceuticals reports YOY increase in Q3 profit

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


Alexion Pharmaceuticals reports YOY increase in Q3 profit

Alexion Pharmaceuticals Inc. said its non-GAAP net income for the third quarter of 2019 was $2.79 per share, up from $2.02 in the third quarter of 2018.

The S&P Global Market Intelligence consensus normalized EPS estimate for the third quarter was $2.48.

The Boston-based drugmaker said its third-quarter non-GAAP net income totaled $635.8 million, an increase from $460.1 million in the year-ago period.

Net product sales rose to $1.26 billion on an annual basis from $1.03 billion, and non-GAAP research and development expenses increased to $186.1 million from $162.3 million spent in the third quarter of 2018.

On a GAAP basis, the company reported $467.6 million, or $2.08 per share, in net income compared to $330.9 million, or $1.47 per share, in the same period a year ago.

In reporting its results, the company updated its earnings forecast for the year. The company, which is in the process of acquiring Achillion Pharmaceuticals Inc. for $930 million, expects to post $10.25 to $10.40 in non-GAAP EPS — up from its previous guidance of $9.65 to $9.85.

GAAP EPS for the year is now expected to be between $8.58 and $8.78 as opposed to $8.13 and $8.41 previously.

The S&P Global Market Intelligence consensus normalized EPS estimate for the year is $10.14.

In other news, the company said its board approved a new share repurchase authorization of $1 billion. The repurchase program does not have an expiration date, and Alexion said it is not obligated to acquire a particular number of shares of common stock.